Golotimod (TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.

Golotimod is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) [1]. Golotimod inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin [2].

T11449L2

C18H20F3N3O7

447.36

Golotimod (TFA);SCV 07 (TFA);Gamma-D-glutamyl-L-tryptophan (TFA);Golotimod (TFA) (229305-39-9 free base)

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years